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1. Introduction 
During the 8th gestational week, a condensation of cells develops on the distal dorsal aspect 
of the digital tip. At week 9, this migrates proximally to form a flat groove, the nail field. At 
week 11, an invagination develops from the proximal groove, which later forms the nail 
pocket or cul-de-sac, with the matrix at its bottom. Nail production starts around week 13. 
At the age of 20 weeks, the nail production is similar to that of an adult. From week 32 on, 
all nail components can be recognized (Lewis, 1954, Zaias, 1963). 
The nail apparatus consists of epithelial and connective tissue components and covers the 
tip of the fingers and toes (Figure 1) (Lewin, 1965, Morgan et al, 2001, Zook et al, 1980). Its 
functions are support, protection and maintenance of the digital tips as well as enhancement 
of the sensory functions of the digital pulps, and the nail is a tool for scratching, defense, 
fine manual work, etc. The cosmetic-aesthetic and social functions of the nail have attained a 
lot of attention in recent years. 
The nail has four epithelial components:  
 The matrix epithelium is the sole structure to produce the nail plate. It is commonly 
divided into the proximal, medial and distal matrix (Figure 2). The existence of a so-
called dorsal matrix is controversial. Most of the matrix is covered by the proximal nail 
fold. Under normal circumstances, its distal portion, the whitish lunula, is only seen in 
the thumb, index and middle finger as well as the great toe; however, manicure with 
pushing the free margin of the proximal nail fold back makes more of the matrix visible 
through the nail and lets the nail plate appear longer. 
The matrix epithelium consists of a basal compartment seen as cuboid basophilic cells that 
migrate up to form the more eosinophilic superficial compartment (Perrin et al, 2004). 
Whenever a nail is avulsed the superficial compartment remains attached to it. During 
onychotisation, the superficial cells undergo nuclear fragmentation. Under normal 
circumstances, there is no granular layer. 
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Fig. 1. Anatomy of the nail apparatus. Oblique view (A) and sagittal section (B) through the 
distal phalanx. 
The matrix contains melanocytes most of which are located suprabasally. In light-skinned 
individuals, they remain functionally inactive. Independent from the skin type, the distal 
matrix contains more melanocytes than the proximal one (Tosti et al, 1994, Perrin et al, 
1997).  
The matrix connective tissue is relatively loose containing blood vessels and a considerable 
number of glomus bodies. Recent studies have found that matrix fibroblasts are CD 10+ 
similar to perifollicular fibroblasts (Lee et al, 2007- 2010). The matrix dermis has an 
important morphogenetic capacity allowing it to reproduce matrix epithelium when enough 
of it is left after trauma or superficial surgical removal. The distance from the most proximal 
matrix epithelium to the bone of the terminal phalanx is about 0.8 – 1 mm (Haneke, 2006, 
Kim et al, 2011). 
 The nail bed epithelium is a relatively thin layer of keratinocytes structurally similar to 
tricholemmal cells. It firmly attaches the nail to the underlying distal phalanx and 
produces a tiny amount of nail bed keratin, which allows the nail plate to virtually slide 
over the nail bed without being detached from it. The nail bed keratin is structurally 
different from the nail plate keratin. The nail bed does not produce nail plate (de Berker 
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and Angus, 1996, Nishi et al, 1996, Zaias and Alvarez, 1968) although this is also 
controversial (Johnson et al, 1991). A normal nail bed does not form a granular layer. 
The nail bed epithelium-connective tissue interface is characterized by unique longitudinal 
rete ridges, in which 3 to 6 layers of longitudinally running capillaries are arranged one 
above the other. Trauma to these capillaries may produce the characteristic splinter 
haemorrhages, which in nail psoriasis are equivalent to Auspitz’ phenomenon of the skin. 
The connective tissue of the nail bed is a firm layer directly attached to the bone without any 
subdermal fat. This and the abundance of nervous structures in the nail bed and matrix are 
probably the reason for the extraordinary pain elicited by trauma to the nail apparatus. 
 The hyponychium is localized at the distal end of the nail bed and forms a particular 
structure allowing the plate to get detached from the bed without injury. It seals the 
virtual space between the nail and the nail bed. The normal hyponychium shows a 
broad granular layer (Hanno et al, 1986, Perrin, 2008). Distal to it, digital pulp skin is 
present. 
 The eponychium is a thin layer of keratin produced by the undersurface of the proximal 
nail fold (PNF). Approximately halfway it divides into the true eponychium remaining 
firmly attached to the dorsal surface of the nail plate and the false eponychium attached 
to the epidermis of the PNF’s ventral surface. It forms the bulk of the cuticle, the 
function of which is to seal the cul-de-sac or nail pocket. 
Proximally and laterally, the nail is ensheathed by the proximal and two lateral nail folds, 
which form a frame leaving the distal margin of the nail plate free. This allows the nail plate 
to grow out and not up. The proximal nail fold is a continuation of the dorsal aspect of the 
skin of the tip of the digit, which folds on itself thereby producing a cover for most of the 
matrix. Its free margin forms an acute angle, which bears the cuticle. This is the most distal 
portion of the false eponychium. When the distal free margin of the proximal nail fold 
rounds up it loses its ability to form a cuticle, and within usually a relatively short period of 
time the undersurface of the proximal nailfold detaches from the underlying nail plate. 
The lateral nail folds are rolls of connective tissue covered with normal epithelium. Their 
border to the nail bed is the lateral nail groove. This is firmly attached to the nail plate 
preventing foreign substances from getting under the nail plate. The lateral grooves are 
important to guide the nails during their forward growth. 
The nail plate – commonly called “the nail” - is the product of the matrix. It is made up of 
keratin which is a sulfur-rich fibrous keratin embedded in a sulfur-rich amorphous matrix. 
The fibrous protein structure is seen clearly under polarized light. In contrast to hair, which 
is made up of exactly the same material, it has no special outer structure like a cuticle of 
scales and the nail grows continuously from birth to death without a cyclical pattern. The 
plate exhibits a slight longitudinal and a more pronounced transverse curvature, the degree 
of which varies between different fingers and toes, during age and some diseases, and has a 
concave border proximally and a convex free margin. The lunula border reflects the shape of 
the matrix as it runs parallel to the proximal border of the nail. Usually three layers of the 
nail plate are distinguished (Figure 2): dorsal (superficial), middle, and deep (ventral). The 
dorsal nail plate layer is produced by the proximal matrix. Its cells are considerably flatter 
and thus, despite its lesser thickness, it has approximately as many cell layers as the 
considerably thicker middle nail plate layer with its higher cells. The dorsal nail plate is 
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responsible for the nail shine. The ventral layer is not true nail but keratin derived from the 
nail bed. Histologically, it is easily distinguished from nail plate. 
 
Fig. 2. Origin of the nail plate layers: The dorsal layer is produced by the proximal matrix 
(pink), the main intermediate and deep nail layer by the intermediate matrix (yellow) and 
the so-called ventral nail layer is the keratin produced by the nail bed (orange). 
The nail organ is an integral part of the functional and sensory finger tip unit (Morgan et al, 
2001). This is formed by the nail apparatus itself, all constituents of the finger tip, the distal 
interphalangeal joints with their capsule, tendons and ligaments. The entheses, insertion 
structures of bone with ligaments and tendons, play an important role for the functional and 
aesthetic integrity of the nail and have recently been found to be of utmost importance in 
psoriatic arthritis and nail psoriasis (McGonagle et al, 2010, 2011). The proximal tip of the 
matrix is just 0.8 to 1 mm from the bone of the terminal phalanx and also very close to the 
distal interphalangeal joint (Haneke, 2006). The joint capsule is enforced by the flexor and 
extensor tendons which form the dorsal and volar aponeuroses. They insert mostly at the 
base of the distal phalanx, but there are also fibers radiating to the more distal dorsal surface 
of the bone and into the connective tissue of the proximal nail fold (Frentz et al, 2000). This 
led some authors to call the nail a musculo-skeletal appendage (McGonagle et al, 2009a, b). 
Thus not only do the complex blood supply of the distal joint and nail, but also the anatomic 
vicinity of matrix and joint give a possible explanation why nail involvement is so frequent 
in psoriatic arthritis patients. 
Nails grow continuously, finger nails about 3 times faster than those of the toes. The 
middle finger of the dominant hand has the fastest growing nail, growing between 3 to 5 
mm per month. A big toenail grows about 1 mm per month. In summer and at daytime, 
the nails grow faster, during winter, at night, in high altitude slower. In psoriatic 
subjects, the nail growth rate is slightly increased. Some drugs also enhance nail growth, 
such as high-dose itraconazole and fluconazole, possibly also cyclosporine. Most 
cytostatic drugs including methotrexate, which is often used as a systemic drug for 
psoriasis treatment, slow down the nail growth rate. Fast growing nails are more prone 
to develop psoriatic pits. 
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2. Histopathologic nail reactions 
In contrast to skin, the nail demonstrates a variety of specific reactions that are sometimes 
opposite to the rest of the skin. Whereas irritation and a number of inflammatory reactions 
cause parakeratosis in skin they may induce a granular layer in the nail, some psoriatic 
reactions included. Several dermatoses that are not characterized by spongiosis, may exhibit 
marked intercellular oedema of matrix and nail bed epithelium, e.g. in ungual lichen planus 
and psoriasis. 
As the dorsal layer of the nail plate is produced by the most proximal portion of the matrix 
any alterations of the proximal matrix will translate into changes of the nail surface and 
uppermost layers. The bulk of the nail is produced by the middle matrix portion; alterations 
here will modify the nail plate both in its thickness as well as optical coherence. When the 
distal matrix is involved the resulting nail alterations will appear at the undersurface of the 
nail (Figure 2). All matrix-derived alterations will grow out with the nail. In contrast, nail 
bed alterations will be seen through the nail, but will not be integrated into the nail. As the 
nail bed keratin moves slower than the nail plate nail bed alterations remain longer or may 
even appear non-migratory. 
Psoriasis of the nails induces characteristic histopathological changes that are 
pathognomonic in the vast majority of cases; however, in the beginning and with less 
pronounced changes it may mimic a spongiotic dermatitis or may be indistinguishable from 
onychomycosis if there is no proof of fungal invasion.  
3. Histopathology of nail psoriasis 
Whereas the main criteria for psoriasis of the skin also apply for ungual psoriasis there are 
some differences and, above all, there are signs not seen in the rest of the skin. 
Pits are the most frequent lesions in nail psoriasis (Figs. 3, 4) with roughly 70% of the 
patients presenting at least some of these characteristic tiny depressions (Zaias, 1969, Tham 
et al, 1988). Histologically, their appearance varies slightly. In the distal nail plate, they are 
seen as a depression in the nail plate surface that may be lined by some parakeratotic nail 
cells. The more proximal the biopsy is taken, the more parakeratosis is left. Under the 
proximal nail fold there are not yet pits but saucer-shaped small areas of parakeratosis. 
When these do not break out as it most commonly happens tiny white spots remain visible 
giving rise to spotted nails. Usually the rest of the nail organ appears normal and only in 
rare circumstances is a tiny inflammatory psoriatic lesion seen at the proximal tip of the 
matrix. Whether or not the pits may also originate from the most proximal portion of the 
ventral surface of the proximal nail fold (Zaias, 1990) remains a matter of dispute. Anyhow, 
it is surprising how rarely the original inflammatory matrix lesions giving rise to spots and 
pits are seen in histopathological slides.  
Nail bed changes are the second most common ungual sign of psoriasis. They may present 
as salmon or oil spots, which represent a small psoriatic plaque of the nailbed entirely 
covered by the nail plate, as onycholysis when the psoriatic plaque extends to the 
hyponychium, or as subungual hyperkeratosis representing a hyperkeratotic psoriatic 
plaque. A typical salmon spot shows slight acanthosis of the nail bed epithelium, an 
inflammatory infiltrate mainly made up of lymphocytes that tend to migrate into the 
epithelium and cause spongiosis, as well as parakeratosis on top of the epithelium, which 
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Fig. 3. Formation of psoriatic pits from a tiny inflammatory focus at the most proximal 
matrix. 
  
Fig. 4. Histological picture of an incipient pit, which is seen as a saucer-shaped mass of 
parakeratosis on the matrix epithelium. 
often contains neutrophils. In more pronounced acute lesions, Munro’s microabscesses may 
be seen. Typical for psoriasis is the arrangement of parakeratosis in obliquely ascending 
columns. This and the lack of fungal elements in PAS stained slides helps to distinguish this 
pattern from onychomycosis, which also often exhibits neutrophil collections as seen in 
Munro’s microabscesses. Psoriatic onycholysis is located more distally in the nail bed, but 
principally very similar to oil spots. The neutrophil exocytosis may be less pronounced, and 
in old lesions it may be difficult to make the diagnosis of nail psoriasis at all as the nailbed 
may develop a granular layer and layered orthokeratotic hyperkeratosis. Subungual 
hyperkeratosis in psoriasis may sometimes be extreme mimicking even pachyonychia 
congenita. Huge thickening of the keratosis with parakeratosis both in horizontal layers and 
oblique columns may be present along with serum inclusions. The latter may form large 
round to oval globules, but also present as very small longitudinal structures. These serum 
inclusions are PAS positive and may be difficult to be dífferentiated by the non-experienced; 
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however, in contrast to fungal elements they are homogeneously positive and have no 
membrane staining like fungi. 
At the hyponychium, the normal granular layer is lost and the tight connection of the nail 
plate with the most distal portion of the nail bed is loosened. Parakeratosis develops 
without attachment with the nail plate. 
Both the matrix and nail bed may transform to an epidermis-like pattern of differentiation in 
old lesions with development of a granular layer and some orthokeratosis. 
Isolated involvement of the middle matrix appears to be less frequent. It leads to nail plate 
changes clinically often seen as psoriatic leukonychia. Histopathologically, the matrix shows 
acanthosis and spongiosis, a dense subepithelial inflammatory infiltrate mainly of 
lymphocytes that also migrate into the matrix epithelium. Neutrophils may be present and 
sometimes concentrate under the nail plate to form spongiform pustule-like collections. 
There may also be parakeratotic layers in the nail plate; these “paronychotic” cell layers are 
distinct from areas of  incomplete nuclear disintegration, which are not infrequently seen in 
avulsed nail strips of ingrown nails. These inclusions of parakeratosis in the nail plate give 
rise to the clinical picture of leukonychia (Fig. 5, 6, 7). 
 
Fig. 5. Psoriatic leukonychia is seen when there is a psoriatic lesion in the middle or distal 
matrix 
Splinter haemorrhages are a characteristic of nail psoriasis not seen in onychomycosis. They 
are analogous to Auspitz’ phenomenon of the skin. When the fragile thinned suprapapillary 
epithelial plate of a psoriasis lesion is traumatized a minute droplet of blood is seen to 
appear in a skin lesion because the epidermis has rete pegs and finger like dermal papillae. 
In contrast, the nail bed is unique to have rete ridges in parallel arrangement; when a 
microbleeding develops it forms a narrow stripe of haemorrhage, about 0.5 – 1mm wide and 
3 – maximally 10 mm long (Fig. 8, 9). They are soon included by newly produced nail bed 
keratin and seen as small blood lakes between the papillomatous appearing keratosis of the 
nail bed and the undersurface of the nail plate. 
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Fig. 6. Munro’s microabscesses in the deep nail plate appear as leukonychic spots in the nail 
 
Fig. 7. This nail plate is irregular in its structure and contains many Munro’s microabscesses 
making it appear intransparent and grayish-white 
Acrodermatitis continua suppurativa is a particular form of pustular psoriasis; however,  
histopathologically three forms exist: with characteristic spongiform pustules, with 
marked spongiosis and even spongiotic vesicles, and a mixed form with spongiform 
pustules and spongiosis. 
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In pustular psoriasis, spongiform pustule formation is usually seen with collection of 
neutrophils gradually increasing in density toward the superficial layers of both the matrix 
and nail bed epithelium (Fig. 10). 
 
 
  
Fig. 8. Splinter haemorrhages develop when there  is haemorrhage in the papillary rete 
ridges or when the horizontally running capillaries thrombose. 
 
 
  
Fig. 9. Longitudinal section of a nail bed biopsy showing oval lakes of blood as sign of 
splinter haemorrhages. 
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a) 
 
b) 
Fig. 10. Acrodermatitis continua suppurativa of Hallopeau with massive spongiform 
pustule formation; a. Huge amounts of neutrophils are seen in the nail bed epithelium, b. 
Collections of neutrophils are embedded in a matrix of cornified nail bed keratinocytes.  
4. Frequency 
Psoriasis prevalence is about 2% in Central Europe and 1-3% worldwide. At any given time 
point, about 10 – 50% of the psoriatics present nail changes (Scher, 1985, Augustin et al, 
2010), but approximately 90% of all psoriatic subjects will have developed nail alterations 
during life time. The prevalence of nail psoriasis in men is about 11% higher than in women 
(Augustin et al, 2010). Isolated nail psoriasis is seen in 1 – 5% (Lavaroni et al, 1994). 
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In a Swiss cohort of 1222 psoriasis patients, 9.4% suffered from nail involvement (Ruprecht 
et al, 2011). 
Whereas there is a striking difference in the frequency of familiar cases between psoriasis in 
Caucasian children (83%) as compared to Asian children (13.4%) ) nail psoriasis is 
insignificantly more frequent in Singaporean (35.8%) than in Dutch children (22.2%). Pitting 
is the most common nail sign (Chiam et al, 2011). The frequency of nail psoriasis appears to 
be similar in Indian children (Nanda et al, 1990). 
Nail psoriasis is more common in psoriatic arthritis, the prevalence is usually greater than 
80%. 
It appears that nail disease is relatively more frequent in males than in females (Wittkowski 
et al, 2011). 
5. Immunogenetics 
Psoriasis is a multifactorial disorder with a strong genetic background. Environmental co-
factors play an important role in its manifestation. Various psoriasis susceptibility 
(PSORS) factors have been identified, of which PSORS1 on chromosome 6p21 has been 
reproduced in all studies.  
Nail psoriasis has more frequently a positive family history as compared to psoriasis of 
the skin (52.7% vs. 43.8%), is more often associated with psoriatic arthritis (29.7% vs. 
11.5%), is more often linked to early onset psoriasis (74.1% vs. 65.5%) and is fewer positive 
for the HLA allele Cw*0602 (33% vs. 50.3%) (Armesto et al, 2011, Gudjonsson et al, 2006). 
It may also be speculated that the IL23R polymorphism that is a common susceptibility 
factor for psoriasis (Cargill et al, 2007) and is not or only rarely found in Han Chinese may 
account for the higher rate of familiarity of psoriasis in Caucasians as compared to Asians 
(Chiam et al, 2011). 
Nail psoriasis is associated with a higher frequency of psoriatic arthritis and a more 
progressive form of the disease (Williamson et al, 2004, Serarslan et al, 2007). The skin and 
nail lesion usually manifest before the arthritis (Mease , 2002). 
6. Clinical lesions of nail psoriasis 
Psoriasis patients with nail involvement have a longer disease duration, higher disease 
severity, more than double the frequency of psoriatic arthritis, more pronounced 
impairment of disease related quality of life, they were statistically significantly longer off 
work, and had a 2.5 fold higher rate of in-hospital treatments (Augustin et al, 2010).  
Nail psoriasis is characterized by pits, salmon spots, onycholysis, subungual hyperkeratosis 
and some more signs that are less frequent. The psoriatic nail changes may be classified 
according to their origin: Pitting, leukonychia, nail plate thickening, crumbling and red 
spots in the lunula originate in the matrix whereas oil drop discoloration (salmon spots), 
nail bed hyperkeratosis, onycholysis and splinter haemorrhages derive from the nail bed. 
Swelling of the proximal nail fold reflects paronychia and swelling of the distal 
interphalangeal joint is suggestive of psoriatic arthritis. Psoriatic pachydermoperiostosis 
leads to enlargement of the entire distal phalanx. 
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Pits are generally said to be the most frequent signs. They are small, well delimited 
depressions on the surface of the nail plate with usually equal size and depth (Figs 11-12).  
   
a) 
  
b) 
Fig. 11. Psoriatic pits are small depressions of the nail surface of equal size and depth. The 
pits in a are artificially stained by dithranol treatment, b shows distal onycholysis in 
addition. 
Analogous lesions are small white to yellowish spots that are mainly seen in the proximal 
nail plate when the parakeratosis does not break off the plate. This is called spotted nails 
(Tüpfelnägel in German), a term not commonly used in the Anglo-American literature. A 
number of ten or more pits per nail or more than 60 pits in all nails is commonly seen as 
proof of psoriasis (Baran & Haneke, 2007). Both pits and spots derive from tiny lesions in the 
most proximal matrix and possibly the most proximal part of the ventral surface of the 
proximal nail fold (Zaias, 1990). The length of a pit represents the length of time of the 
psoriatic matrix lesion, its width is indicative of  the width of the lesions and the depth 
either of the severity of the lesion or a lesion that extends a bit into the intermediate matrix. 
Pits are usually arranged irregularly but sometimes they form longitudinal or even  
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a)      b) 
 
b) 
Fig. 12. a - c. 16-year-old boy with marked nail psoriasis. Note that some nails are almost 
destroyed, other are much less involved. 
transverse rows. Longitudinal rows of pits are due to repeated minor trauma at exactly the 
same location of the proximal matrix whereas transverse ones may reflect a trauma that 
elicited a Köbner phenomenon at many spots at the same time. Rarely, shallow transverse 
lines are seen indicating a microtrauma to the entire width of the matrix. The variable 
arrangement of the pits may cause a clinical picture that varies within a relatively short 
period of time. It is now thought that pits may be due to microtrauma of the proximal 
matrix, which is the closest to the articulation, from the distal interphalangeal joint. Pits in 
horizontal rows are equivalent to Beau’s lines (Fig. 13). 
In pustular psoriasis, pits may occur that are much larger than usual pits (Fig. 14); they are 
also called elkonyxis.  
Salmon or oil spots represent circumscribed psoriasis plaques of the nail bed. Their specific 
colour is due to the fact that the psoriatic scales are compressed under the nail plate and 
imbibed with serum that makes them appear yellowish-reddish mimicking a drop of oil on 
a sheet of paper. Once a psoriatic plaque has reached the hyponychium or when it started at 
the hyponychium the scales are not or no longer compressed by the overlying nail plate and 
may break out giving rise to onycholysis (Fig 15).  
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Small lesions in the intermediate and distal matrix may appear as red spots whereas 
extensive lesions may cause a red lunula before the resultant nail plate changes obscure 
these alterations. 
 
a) 
  
b) 
Fig. 13. Pits arranged in horizontal rows. On finger nails, which grow faster they are still 
identifiable as single pits (A) whereas on toenails, due to their slow growth rate they appear 
as transverse furrows and lines (B). 
Sometimes, psoriasis of the nail bed may cause important hyperkeratosis that may in 
extreme cases resemble pachyonychia congenita. In addition to subungual hyperkeratosis 
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there may also be a thickening of the nail plate itself. Clinically this looks like a rough nail 
with irregular surface and loss of transparency, which is mainly due to wavy arrangement 
of the nail lamellae as well as inclusion of serum and neutrophilic abscesses. 
 
Fig. 14. Nail involvement in pustular psoriasis of the palms and soles (Barber-Königsbeck 
type). Note the relatively large pits and some ivory-coloured spots. These large surface 
depressions are called elkonyxis. 
Small dark-brown to black longitudinal streaks in the nail bed, mainly in distal location, are 
called splinter haemorrages (Fig 16). They are due to thromboses of the dilated capillaries of 
the nail bed papillary ridges, which run all along the nail bed with 3 to 5 layers of capillaries 
one above the other. 
Psoriatic leukonychia is relatively rare. It usually represents a focus of parakeratosis in the 
intermediate nail layers. It is often associated with other signs of nail psoriasis and may be 
seen as an advancing edge in acute-onset nail psoriasis. 
Larger psoriatic lesions of the nail matrix cause crumbly nails, even complete nail 
destruction. They are often associated with psoriatic arthritis.  
Pustular psoriasis of the nails is seen in palmar plantar pustular psoriasis of Barber-
Königsbeck (Figures 14, 17), in generalized pustular psoriasis of von Zumbusch and in 
Hallopeau’s acrodermatitis continua suppurativa. In palmar plantar pustular psoriasis, nail 
involvement is commonly seen as yellow lakes of pus under the nail plate. This is often 
associated with elkonyxis. In generalized pustular psoriasis, nail involvement usually leads 
to nail dystrophy. 
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a) 
  
b) 
Fig. 15. Subungual hyperkeratosis in distal nail bed psoriasis. A. Fingernails, B toe nails. 
Acrodermatitis continua suppurativa of Hallopeau is an insidiously developing disease of the 
tip of the finger commonly commencing dorsally and slowly involving the nail apparatus 
(Figs. 18, 19 a, b). The diagnosis is often only made late when there is already a certain degree 
of nail dystrophy. In very typical cases, the finger or toe tip rounds up, loses its nail, the skin is 
fiercely red with some tiny pustules. Radiographically, resorption of the corona unguicularis 
becomes evident. In acute cases, the skin may appear superficially necrotic. 
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Fig. 16. Splinter haemorrhages in a nail with salmon spot 
  
Fig. 17. Psoriasis pustulosa of Barber-Königsbeck 
 
Fig. 18. Early acrodermatitis continua suppurativa  
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a) 
  
b) 
Fig. 19. Acrodermatitis continua suppurativa. A. Pustules have been present for more than 
12 years in this elderly lady. B. Relatively acute onset of acrodermatitis continua 
suppurativa in a patient with bronchial carcinoma; whether this is a causal or accidental 
association is not clear. 
Psoriatic paronychia develops when the periungual skin is affected by psoriasis, but it is also 
commonly seen in psoriatic arthritis with nail involvement (Fig. 20). The chronic inflammation 
causes thickening of the free edge of the proximal nail fold with consecutive loss of the cuticle 
and later loss of attachment of the nail fold’s ventral surface to the underlying nail plate. This 
allows foreign material such as dirt, microorganisms or allergenic substances to enter the space 
under the nail fold where they may aggravate the inflammation. 
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Fig. 20. Psoriatic paronychia in a patient with psoriasis arthropathy. 
Psoriatic enthesitis of the distal interphalangeal joint is a painful inflammation of the 
insertions of tendons and ligaments mainly at the base of the distal phalanx. This may cause 
swelling of the distal joint with stiffness and loss of the dorsal creases of the distal 
interphalangeal joint and a shiny skin.  
Psoriatic pachydermoperiostosis is a rare event. It is associated with bone appositions which 
also lead to a widening of the base of the distal phalanx with consecutive widening of the 
nail plate. 
In almost a quarter of the patients with latent psoriatic arthritis, radiological assessment will 
detect changes not seen clinically (Khan et al, 2003). 
7. Quality of life 
Nail psoriasis has been shown to severely impair quality of life (see Scoring of nail 
psoriasis). Pain, cosmetic embarrassment, impaired function, loss of dexterity are just some 
of the complaints brought forward by the patients (De Jong et al, 1996). More than 90% of 
the patients consider their nail psoriasis to be a significant social problem affecting their 
professional work, and more than  half of them experienced pain (de Berker, 2009, Gupta 
and Cooper, 2009).   
7.1 Scoring of nail psoriasis 
To score the extent and severity of nail psoriasis the nail psoriasis severity index (NAPSI) 
was developed (Rich and Scher, 2003). Each nail is divided into 4 quadrants by a horizontal 
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and a vertical line. Nail matrix and nail bed are scored independently. Any of the matrix 
signs – pitting, leukonychia, red lunula spots and crumbling – as well as the nail bed  signs – 
onycholysis, salmon or oil spots, subungual hyperkeratosis, splinter hemorrhage – are 
counted. Absence is given 0, presence in one quadrant 1, presence in two quadrants 2 etc 
up to 4 quadrants receiving 4. Matrix and nail bed signs are added resulting in a 
maximum score of 8 per nail. All finger nails can have a maximum NAPSI score of 80, 
finger and toenails of 160. All of the 8 individual features of matrix and nail bed psoriasis 
are just given one score independent from their number per quadrant. For a target nail, 
the same technique can be used to evaluate all 8 parameters (pitting, leukonychia, red 
spots in lunula, crumbling, oil drop, onycholysis, hyperkeratosis, and splinter 
hemorrhages) in each quadrant of the nail, giving that one nail a score of 0-32. The NAPSI 
is a useful tool for nail evaluation in the course of therapeutic studies, both for the effect 
on all nails as well as for the judgment of a target nail (Rich and Scher, 2003). 
Interobserver reliability for the total NAPSI score is good whereas the nail score only 
shows moderate agreement (Aktan et al, 2006). 
The NAPSI has some limitations. It does not consider the number of pits or red spots of 
the lunula per quadrant nor the size of an oil spot or the thickness of subungual 
hyperkeratosis. This limits its use to assess improvement  in the course of a treatment 
(Parrish et al, 2004). Therefore, an additional gradation was proposed for each sign from 
absent (= 0), mild (= 1), moderate (= 2) and severe (=3) as a qualitative scale similar to that 
used in the Psoriasis Area and Severity Index (PASI). Nail crumbling is given the same 
score like a pit, but is considerably more severe. Pustular psoriasis and psoriatic arthritis 
are not included in the NAPSI. 
A modified NAPSI was developed for patients with psoriatic arthritis (Maejima et al, 2010). 
This modified NAPSI is higher in patients with psoriasis of the proximal nail fold, distal 
interphalangeal (DIP) joint arthritis whereas there was no correlation with the modified 
NAPSI and other systemic signs. Nail psoriasis was assumed to be related to the Koebner 
phenomenon and local inflammatory DIP joint arthritis in PsA patients, and nail 
involvement in PsA was suggested to be among the disorders indicative of distal phalanx 
enthesitis (Tan et al, 2007, Elder et al,2010). 
Nail psoriasis has both a physical and psychological impact on the patients negatively 
influencing their quality of life (QoL). A nail psoriasis quality of life index (NPQ10) was 
developed to measure life quality impairment due to nail psoriasis and its modification in 
the course of treatment (Ortonne et al, 2010). Again, psoriatic arthritis patients are not 
included in the NPQ10. Of the 17000 members of the French Association pour la lutte contre 
le psoriasis, 4000 were asked to fill in a questionnaire regarding the physical aspects of nail 
psoriasis. Roughly one third responded and 795 of them had nail psoriasis. The items were 
elaborated by physicians and patients alike. The patients rated their nail psoriasis as 
bothersome in 86%, as unsightly in 87%, and as painful in 59%. The number of nails 
involved significantly affected the pain, aesthetic and functional impairment. Whereas 86% 
received therapy, 72% were dissatisfied with their treatment. From these facts, 10 questions 
were created, only one of which concerned pain, the other 9 were related to functional 
handicaps in daily life. Answers are scored from 0 to 2 with 0 being ’no without hesitation’ 
(absent) or ‘not painful’, 1 not for ‘yes sometimes’ or ‘not very painful’, and 2 for ‘yes 
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without hesitation’ or ‘very painful’. Item 2 and 6 are specific for toe and finger nail 
psoriasis, respectively. Item 7 relates only to patients driving a car. Scores are transferred 
into percentages in order to be able to compare them always resulting in a maximum of 100. 
A test-retest questionnaire was sent out to a few patients yielding a very good 
reproducibility. NPQ10 scores are significantly higher in patients having both finger and toe 
nail psoriasis, in female psoriatics, and in patients with a shorter history of psoriasis 
(Ortonne et al, 2010). The NPQ10 score shows good correlation with the dermatology life 
quality index (DLQI) (Finlay and Khan, 1994). 
 
State the location of your psoriasis of the nails 
1. Fingernails  2. Toenails  3. Both 
1. Would you say that your psoriasis of the nails is mostly: 
          1. Very painful  2. Not very painful   3. Not painful 
2. Because of my psoriasis of the nails, I have difficulty putting my shoes on: 
          1. Always   2. Sometimes   3. Never 
3. Because of my psoriasis of the nails, I don’t do any of the jobs I usually do around the 
house: 
          1. Always    2. Sometimes    3. Never 
4. Because of my psoriasis of the nails, I get dressed more slowly than usual: 
          1. Always   2. Sometimes    3. Never 
5. Because of my psoriasis of the nails, I have trouble putting on my socks (or stockings 
or tights): 
          1. Always    2. Sometimes    3. Never 
6. Because of my psoriasis of the nails, I have trouble turning my door key: 
          1. Always    2. Sometimes    3. Never 
7. Because of my psoriasis of the nails, I have trouble driving my car: 
          1. Always   2. Sometimes    3. Never 
8. Because of my psoriasis of the nails, someone helps me to get dressed: 
          1. Always   2. Sometimes    3. Never 
9. Because of my psoriasis of the nails, I avoid doing big jobs around the house: 
          1. Always    2. Sometimes    3. Never 
10. Because of my psoriasis of the nails, I am more irritable than usual, and bad-
tempered with people: 
          1. Always    2. Sometimes    3. Never 
Table 1. Questionnaire of the NPQ10 (Ortonne et al, 2010) 
The psoriasis weighted extent and severity index (PWESI) evaluates the skin disease on a 
scale from 0 (none) to 4 (extensive) and severity of skin disease on a scale of 0 to 4 (intensely 
inflamed). Ten areas are assessed, among them hands/fingers/fingernails (Wittkowski et al, 
2011). 
The extended 10-area linear psoriasis area and severity index (XL-PASI) combines the 
PASI and PWESI scoring methods (Feldman and Krueger, 2005) and includes the 
assessment of surface area involved as well as dimension for scaling, erythema, thickness 
and joint involvement for specific areas of psoriatic involvement. As with the PASI, severity 
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is graded from 0 to 4 and body surface is divided into ten areas and each is quantified. The 
XL-PASI scale ranges from 0 to 148 (Wittkowski et al, 2011). 
8. Differential diagnosis of nail psoriasis 
There is a wide range of potential differential diagnoses, the most important of which are 
onychomycoses (Table 2) and nail dystrophies after minor trauma, in chronic venous 
insufficiency and impairment of the peripheral circulation. 
Onychomycoses are the most frequent nail disorders. Distal and distal-lateral subungual 
onychomycosis (DLSO) are mainly due to dermatophytes with Trichophyton rubrum being 
the most frequent pathogen although T mentagrophytes (interdigitale) also plays an 
important role. All other dermatophytes are rather rare and the role of most yeasts and non-
dermatophyte moulds as primary nail pathogens remains disputed. DLSO begins at the 
hyponychium from where the fungus slowly invades the nail bed in the direction toward 
the matrix. The infection apparently irritates the nail bed epithelium that produces a reactive 
hyperkeratosis, which harbours most of the fungal elements whereas the nail plate rather 
acts as a barrier. In contrast to psoriatic onycholysis that exhibits the classical salmon spot 
colour at its proximal margin, mycotic onycholysis has no reddish-brown margin (Fig 21 
a&b). Nail psoriasis and onychomycosis may coexist (Natarajan et al, 2010). 
 
 Onychomycosis Psoriasis 
Pits Rare Very frequent 
Onycholysis Frequent Frequent 
Discoloration Yellow – brown None - yellow 
Loss of nail 
transparency 
Frequent Less frequent 
Fungi Very frequent, depends on type of 
OM 
rare 
Transverse ridges Rare Rare 
Splinter haemorrhages Almost never Rare 
Leuconychia Depends on onychomycosis type:
Superficial white OM 
Proximal white subungual OM 
Rare 
Paronychia In onychomycoses due to moulds In psoriatic arthritis and 
periungual psoriasis 
Finger vs. toe 
involvement 
Toe nails 7 to 10 times more often 
infected 
Finger nails more often 
affected by psoriatic 
alterations 
Other skin lesions Tinea pedum and/or manuum Psoriasis elsewhere 
Heredity Autosomal dominant 
susceptibility to get a 
dermatophyte nail infection 
Frequent familiarity, 
particularly in early onset 
psoriasis and HLA-Cw6 
positive subjects 
Table 2. Differential diagnostic clinical signs in onychomycosis (OM) and nail psoriasis 
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a) 
  
b) 
Fig. 21. Psoriatic onycholysis demonstrates a livid-red proximal margin (A), which is not 
seen in mycotic onycholysis (B). 
There are also many histopathological signs in common of onychomycosis and nail psoriasis 
(Table 3). This may render the differential diagnosis between these two frequent nail 
conditions very difficult if not impossible. Furthermore, it is possible that both 
onychomycosis and psoriasis are present in the same subject in different digits as well as in 
the same nail (Fig.22). It is therefore self-evident that a specimen sent for histopathological 
diagnosis of nail psoriasis is also stained with periodic acid-Schiff (PAS) or another fungal 
stain like silver-methene amine (Grocott). 
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Fig. 22. This nail histopathology shows both psoriasis and onychomycosis: on the surface, 2 
pits are seen; the nail itself is a bit wavy and displays fungal hyphae seen as fine 
eosinophilic lines in the deep layer of the nail  in this haematoxylin & eosin stain section; at 
the undersurface of the nail there is loose keratin, which is mostly parakeratotic and 
contains several Munro’s  microabscesses. 
 
 Onychomycosis Psoriasis 
Subungual hyperkeratosis 
 
Marked hyperkeratosis 
with accumulation of 
neutrophils and serum 
globules  
Marked hyperkeratosis 
with accumulation of 
neutrophils and serum 
globules  
Nail bed and matrix 
granulosis 
Patchy hypergranulosis Patchy hypergranulosis 
Nail bed hyperplasia Papillomatous hyperplasia 
of nail bed 
Papillomatous hyperplasia 
of nail bed 
Spongiosis and exocytosis Spongiosis and 
mononuclear exocytosis 
Spongiosis and 
mononuclear exocytosis 
Surface alterations Usually not present Cup-shaped depression of 
nail plate surface with 
parakeratosis: psoriatic pit  
Demonstration of fungi Hyphae and spores in 
subungual  hyperkeratosis 
and undersurface  of nail 
plate 
May be present in double 
pathology 
Table 3. Histopathological differential diagnosis of nail psoriasis and onychomycosis 
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Reiter’s disease is an infrequent reactive arthritis with changes of the ocular, genital and oral 
mucosae such as conjunctivitis, blepharitis, scleritis or iridocyclitis, balanitis, vulvitis or 
stomatitis circinata, which are virtually indistinguishable from lingua geographica and its 
very rare extralingual analogues, and painful inflammation of joints and the vertebral 
column. Many patients are HLA-B27 positive. Nail changes often start with pits and salmon 
patches remaining indistinguishable for a long time from nail psoriasis (Pajarre et al, 1977, 
Lovy et al, 1980) before the nails become destroyed (Fig. 23) (Table 4). 
 
Fig. 23. Reiter’s disease of the nails (Courtesy T Ruzicka, Munich) 
 
 Psoriasis Reiter‘s disease 
Pitting Very frequent Less frequent 
Onycholysis Frequent Frequent 
Subungual keratosis Variable Pronounced 
Salmon patch Reddish More brown 
Nail destruction Rare Marked 
Skin lesions 
elsewhere 
Frequent Palmar and plantar lesions, joint changes, 
mucosal lesions 
Table 4. Differential diagnosis of nail psoriasis and nail changes in Reiter’s disease 
Onycholysis is often due to overzealous manicure, but psoriasis of the nails renders them 
more susceptible to develop onycholysis due to minor trauma. Again, psoriatic onycholysis 
has usually a reddish proximal margin, which is lacking in onycholysis semilunaris (Fig. 24). 
Eczema involving the nail apparatus usually causes pit-like depressions leading to a rough 
nail surface called trachyonychia as well as to irregular transverse lines. The depressions are 
commonly less deep and less regular in size than in psoriasis. Although these depressions 
are more common in allergic contact dermatitis and nummular eczema they are also seen in 
atopic eczema (Nnoruka et al, 2004). Despite the trachyonychia, the nail may still retain its 
shine. In contrast, subungual contact dermatitis, e.g. as seen in acrylate allergy, causes 
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subungual hyperkeratosis and later onycholysis as well as loss of nail transparency  and 
shine (Hemmer et al, 1996). 
 
a) 
  
b) 
Fig. 24. Onycholysis semilunaris (A) is characterized by its half-moon shape and clear 
border whereas psoriatic onycholysis has the typical appearance of an oil spot at its 
proximal margin (B). 
When many or even all nails are affected the condition is called twenty nail dystrophy; this 
may, however, be a manifestation of ungual lichen planus, alopecia areata, eczema or 
psoriasis and the exact diagnosis often requires a histopathological examination of a nail 
biopsy. 
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Irritant contact dermatitis was also estimated to mimic nail psoriasis (Takeuchi et al, 
2010). 
Alopecia areata is known to be associated with rough nails. The more extensive the 
alopecia areata is the more likely the patients also get nail changes. Most probably, 
isolated alopecia areata of the nails does exist (Tan et al, 2002, Nanda et al. 2002). Alopecia 
areata nails grow slower than psoriatic nails. They are often indistinguishable from 
eczema nails, and in fact, both have a microscopical spongiotic dermatitis in common. 
Serum is in the spongiotic vesicles and becomes included into the nail; when it is very 
superficial it may break out and leave a depression, but when the origin is in the 
intermediate matrix the dried serum will remain in the nail and be the reason for the loss 
of nail transparence, nail thickening and brittleness. 
When almost all nails are affected the so-called twenty-nail dystrophy is diagnosed 
(Samman, 1979). Even though this term does note denote a specific condition it is still 
widely used, particularly for 20-nail dystrophy of children (Horn and Odom, 1980, Baran 
and Dawber, 1987). 
9. Treatment of nail psoriasis 
Psoriasis of the nails is an often neglected or overlooked disease as is evidenced by the most 
recent 100-page strong guidelines on psoriasis treatment (Nast et al, 2011), and it has a 
serious impact on the individual’s daily life.  
The therapy of nail psoriasis is difficult, particularly that of isolated nail psoriasis as one 
usually hesitates to treat it systemically. In general, systemic treatment regimens that are 
effective in cutaneous psoriasis also improve nail lesions. There is a general lack of well-
documented studies and they are often not or difficult to compare (Jiaravuthisan et al, 2007) 
and few evidence-based treatments exist (Cassell and Kavanaugh, 2006). A standardized 
therapeutic approach does therefore not exist and preferred treatment regimens also differ 
between various countries. The treatment also depends on the nail structure involved, how 
severe the nail dystrophy is, whether there are extraungual lesions, the time needed for 
applying a specific therapy, and not the least also on its cost. 
9.1 Topical therapy 
Topical treatments are generally held not to be very effective. This has several simple 
reasons: Pits come from the depth of the nail pocket where the lesions are protected by the 
overlying proximal nail fold from being treated; lesions in the intermediate matrix are both 
hidden by the proximal nail fold and the nail plate; nail bed lesions are under the nail plate, 
which is a considerable obstacle to penetration of drugs. Ointments applied on finger nails 
may interfere with paper work. There are very few controlled studies on topical therapies. 
Urea (carbamide) is known for its keratolytic property. A paste containing 40% urea 
(Onyster®) softens fungus infected nails to a degree that it can be atraumatically removed; 
this may be a starting point for topical teatment. A 10% urea nail varnish was shown to 
improve the biophysical properties of the nail (Krüger et al, 2006). A 15% stable urea nail 
lacquer (Onypso®) is advertised as “the only specific topical treatment for nail psoriasis” as 
it is claimed to reduce subungual hyperkeratosis. No controlled studies are available. 
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Anthralin (dithranol, cignoline) suppresses cell proliferation, inhibits neutrophils and 
monocytes, neutrophile migration and lymphocyte proliferation. It exerts a strong 
antiproliferative action on keratinocytes (Schröder et al, 1985). It is an old, extremely safe 
and very effective psoriasis remedy. Anthraline 0.4 to 2% in petrolatum was used in a study 
of 20 patients over a period of approximately 5 months (Yamamoto et al, 1998). There was 
no response in 8 and little to fair response on onycholysis, subungual hyperkeratosis and 
pitting in 12 individuals. Anthraline is not popular because it stains skin and clothes. 
Therefore the patients washed the anthraline ointment off after 30 minutes and applied 10% 
triethanol amine. However, nail staining cannot be completely avoided making the lesions 
even more obvious and embarrassing. 
There are no studies on anthralin in combination with ultraviolet (Ingram regimen) or coal 
tar without or with UV (Goeckerman regimen) in nail psoriasis. 
5-Fluorouracil (5-FU) is a cytostatic agent inhibiting nucleic acid synthesis and thus 
reducing cellular renewal. It was mainly used for the treatment of actinic keratoses and 
superficial basal carcinomas, but the application under occlusion or twice daily until an 
erosive reaction was achieved did not make it popular amongst the patients. A prospective 
study on 20 patients with very long-standing psoriatic pitting, hyperkeratosis or onycholysis 
was conducted with 1% 5-FU solution twice daily. This had to be massaged into the skin 
immediately adjacent to the nail for 6 months. Seventeen of the 20 subjects experienced 
marked improvement in pitting and subungual hyperkeratosis (Fredriksson, 1974). One 
patient with onycholysis lost all affected nails that finally regrew but with the same 
onycholysis as before.  
In a double blind controlled study, 5-FU in a penetration enhancer consisting of urea and 
propylene glycol was compared to the penetration enhancer solution alone. The preparation 
was applied once daily over a period of 12 weeks. There was a statistically significant 
improvement of the total nail area severity (NAS) score comprised of the number of pits, 
degree of pitting, subungual hyperkeratosis, onycholysis and salmon spots, for both 
preparations with no superior results seen in the 5-FU group (de Jong et al, 1999). Six 
subjects in the 5-FU group experienced side effects such as pain, swelling, inflammation, 
discoloration, onycholysis, and nail perforations. 5-FU is not widely used anymore. 
Topical steroids have been and continue to be the most commonly used therapeutic agents 
for local treatment of nail psoriasis. They exert an anti-inflammatory and 
immunosuppressive action, inhibit leukocyte migration into the skin, decrease vascular 
permeability, reduce the effect of pro-inflammatory cytokines, and have an antiproliferative 
action. All these effects taken together make them a good treatment of nail psoriasis 
provided they can reach the psoriatic lesion of the nail. However, no standard therapeutic 
regimes exist for topical steroid  therapy of nail psoriasis (Jiaravuthisan et al, 2007) as there 
are very few controlled studies with their use in nail psoriasis. Generally, high-potency 
topical steroids are prescribed that are applied once or even twice daily to the nail folds and 
nail bed either as a cream, ointment or solution. Once an effect has been achieved the 
frequency of application is reduced until about twice weekly. A proactive treatment 
approach may be superior although there are no controlled studies in nail psoriasis. Side 
effects of long-term potent topical steroid use are hypopigmentation and skin atrophy with 
development of telangiectasiae. It may be wise to have the patient apply antiseptics once 
daily during this treatment as the risk of microbial growth, particularly of Candida spp, may 
www.intechopen.com
 Nail Psoriasis 
 
169 
be considerable. Topical corticosteroid application has even been linked to tapering of the 
digits and to phalangeal bone resorption (Wolf et al, 1990). 
A study on 10 nail psoriasis patients with 8% clobetasol nail lacquer resulted in reduced 
pitting, onycholysis and salmon spots after only 3 months of treatment. The treatment was 
found to be safe, effective and cosmetically acceptable (Sanchéz Regaña et al, 2005). 
Betamethasone diproprionate – salicylic acid ointment over 3 to 9 months reduced the nail 
bed hyperkeratosis by about one half (Tosti et al, 1996), which was virtually identical to the 
effect of calcipotriol. The authors’ conclusion was that calcipotriol is a safe alternative to 
topical steroids in nail bed psoriasis.  
A combination treatment with calcipotriol cream and clobetasol cream was shown to reduce 
subungual keratosis by 72% after 6 months and 81% after 12 months in finger nails whereas 
the improvement was 70 and 72.5% in toe nails, respectively (Rigopoulos et al, 2002). For the 
first 6 months, calcipotriol cream was applied on weekday evenings and clobetasol cream on 
weekend evenings, the next 6 months only clobetasol cream was used. Side effects of 
calcipotriol in the treatment of nail psoriasis are rare and mild, they mainly consist of 
irritation, burning, erythema and diffuse urticaria (Tosti et al, 1996, Rigopoulos et al, 2002). 
Cyclosporine is an immunosuppressive calcineurin inhibitor ultimately decreasing T cell 
growth and migration (Baker et al, 1987). A 10% formulation in maize oil was used in three 
fingers of a patient (Tosti et al, 1990) with marked improvement after 2 months and almost 
complete clearing after 3 months. No adverse effects were observed. Cyclosporine is a 
hydrophobic, large molecule of 1.5 kD and difficult to incorporate into a topical preparation, 
but the newer calcineurin inhibitors tacrolimus and pimecrolimus are available as ointment 
or cream, respectively. Curiously, no controlled study with any of these two potent drugs 
has been conducted in nail psoriasis. Tacrolimus was found to be ineffective in plaque 
psoriasis, most probably due to insufficient penetration because of its large molecular 
weight of 802 Da, and this might have discouraged investigators to try it in nail psoriasis. 
Tazarotene is a third-generation topical retinoid for the treatment of acne and psoriasis. It 
binds to the nuclear retin acid receptors RAR- and RAR- exerting an effect on epidermal 
proliferation and differentiation. Its action in psoriasis is mainly normalization of abnormal 
keratinocyte proliferation and control of inflammation (Kang et al, 1996). In addition to 
some case reports on tazarotene use in periungual psoriasis, a double-blind controlled study 
was performed with the vehicle as the control. Both tazarotene 0.1% under occlusion as well 
as without occlusion yielded a statistically significant better reduction in onycholysis and 
pitting (Scher et al, 2001). Erythema, peeling of the paronychia, irritation of the finger skin 
and paronychia were the side effects seen in the tazarotene group whereas the vehicle was 
tolerated without adverse effects. 
Indigo naturalis is a dark-blue powder from the leaves of indigo-bearing plants. It inhibits 
proliferation, promotes differentiation of epidermal keratinocytes, inhibits neutrophil 
proinflammatory responses and suppresses TNF- induced vascular cell adhesion molecule 
1 expression in endothelial cells thereby exerting an antipsoriatic effect (Lin et al, 2009). Six 
patients with psoriasis who had been treated for 4 years with indigo naturalis ointment or 
systemic Chinese herbs and whose skin lesions had responded well whereas the nails 
remained unchanged were treated twice daily with 1 to 2 drops of indigo naturalis oil 
extract onto the nail plate, fold and hyponychium. After three months, the mean reduction 
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in PASI was 51%, and two patients had even PASI reductions of 89 and 82%, respectively. 
No adverse side effects were noted (Lin, 2011). 
9.2 Intralesional treatments 
Intralesional injections of corticosteroids are widely used, either with an injection needle 
or by a high-pressure injector (Dermojet®, Port-O-Jet®). In most cases, crystal suspensions 
of triamcinolone acetonide are used with variable concentrations of 1 mg/mL (Zaias,1990) 
to 10 mg/mL (Scher and Daniels, 2003, de Berker and Lawrence 1998). Injections ranged 
from a single one (Gerstein, 1962) to once every 3 to 4 weeks for 4 to 6 months (Abell and 
Samman, 1973, Zaias, 1990) or monthly for the first 6 months and then 4 injections over 
the next 6 months followed by once every two months for the next 6 to 12 months 
(Norton, 1982). It appears that the number of affected nails may be a limiting factor as 
many patients complain of discomfort and pain. In our experience, even though most 
patients prefer the needle-less high pressure air gun they admitted that injection with a 
30-gauge needle is less painful (unpubl. observation). The sort of high pressure injector 
appears to be important as there are good results with some devices and disappointing 
ones with others. Side effects of high pressure devices are subungual haematomas, short-
term paraesthesias, atrophy at the injection site, epidermoid inclusion cysts (de Berker, 
2000), tattooing with minute rubber particles and blood splash back on the instrument  
and the physician. 
Most intralesional injections are given into the proximal nail fold, best one each into each 
side of it with sparing the central area where the extensor tendon inserts in order to avoid 
steroid-induced tendolysis. These injection sites are good for lesions originating from the 
matrix, i.e. pits, ridges and severe nail plate dystrophy whereas nail bed-derived lesions 
such as subungual hyperkeratosis and salmon spots profit from sub-nailbed injections. 
These are, however, even more painful and usually require an anaesthesia to be applied. 
The concentration of triamcinolon per mL does not appear to be critical as there are 
variations from 1mg/mL to 10 mg/mL in the literature. Higher concentrations allow 
smaller volumes to be injected, which then is less painful. It is still a matter of debate 
whether lidocaine or another local anaesthetic should be used to dilute the triamcinolone 
solution. In our opinion, it is both the needle prick and the pressure from the injection that 
are felt as uncomfortable to painful and no local anaesthetic can prevent this. Topical 
anaesthesia may be used, for instance with lidocaine-prilocain mixture (EMLA®), to 
alleviate the needle prick. 
Intralesional methotrexate (MTX) has recently been used in a single patient (Sarıcaoglu et 
al, 2011). MTX is a folic acid analogue irreversibly binding to dehydrofolate reductase thus 
blocking deoxyribonucleic acid synthesis. In addition, it was shown to exhibit an anti-
inflammatory effect by inhibiting the polyamine pathway in autoimmune diseases. 
Intralesional MTX has been shown to be effective and safe in a variety of conditions 
(Agostini et al, 2007). This was the rationale to use it in a psoriatic patient with pitting and 
subungual hyperkeratosis of only one nail. MTX 2.5 mg was injected into each side of the 
proximal nail fold once weekly for 6 weeks. Pain was tolerable. During the 4-month follow-
up, the psoriatic nail alterations improved and no clinical or laboratory side effects were 
noted. No recurrence of the nail lesions was observed in the following two years. 
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Although intralesional cyclosporine has shown good effects in cutaneous psoriasis there 
are no reports on intralesional cyclosporine in nail psoriasis. 
9.3 Physical treatment modalities 
9.3.1 Phototherapy and photochemotherapy 
Phototherapy has been used for psoriasis for more than 100 years. Ultraviolet (UV) is known 
to exert an immunosuppressive effect through an effect on local and circulating immune 
cells, particularly on dendritic cells. Narrow band UV B of 311 nm has been shown to be 
most effective. Photochemotherapy combines the use of UV, usually UV A, with the topical 
or systemic administration of a photosensitizing agent, most commonly a psoralen. In 
contrast to skin psoriasis, nail psoriasis barely responds. In a study with oral PUVA on 10 
patients, the skin of the proximal nail fold improved, but pitting did not improve. Nail plate 
crumbling cleared in three out of 4 individuals whereas onycholysis and oil drops improved 
slightly by approximately 50% (Marx and Scher, 1980). In contrast, in a retrospective study 
on the effect of different systemic treatments, PUVA improved the NAPSI score after 12, 24 
and 48 weeks by 21%, 51% and 69%,  Re-PUVA (combination of a retinoid with PUVA) by 
27%, 65%, and 85%,  ReNUVB (retinoid plus narrow-band UV B) by 21%, 48% and 64%, 
respectively, whereas narrow-band UV B alone had no beneficial effect (Regana et al, 2011). 
Topical PUVA resulted in clearing of 2 subjects with pitting and 2 with onycholysis 
improved substantially (Handfield-Jones et al, 1987). Even these results are surprising as the 
nail is a very efficient UV shield (Stern et al, 2011). 
9.3.2 Laser treatment 
Various studies have shown efficacy of laser treatments on cutaneous psoriasis. As 
angiogenesis was found to be one of the driving factors in psoriasis pathogenesis 
(Heidenreich et al, 2009) most studies were performed with the pulsed dye laser, which 
specifically targets blood vessels (Taibjee et al, 2005, Bovenschen et al, 2006). Two recent 
studies used the pulsed dye laser for nail psoriasis, one in comparison with photodynamic 
treatment (Fernández-Guarino et al, 2009), the other evaluated the effect of PDL on nail 
psoriasis (Oram et al, 2010). A third study not yet published (Treewittayapoom et al, in 
press) used two different pulse widths. All studies used a 595-nm pulsed dye laser with a 
spot size of 7 mm. The pulse duration in the Spanish study was 6 ms, in the Turkish one 1.5, 
and the Thai one compared the efficacy of 6 ms with 0.45 ms pulse width, fluences were 9, 8 
– 10, and 9 and 6 J/cm², respectively. Both the PDT and the PDL group showed a decrease in 
the NAPSI score with no difference between the two groups (Fernández-Guarino et al, 
2009). The Turkish study showed an improvement mainly of the nail bed NAPSI (Oram et 
al, 2010). The Thai study did not demonstrate a difference in treatment outcome between the 
long 6 ms pulse with 9 J/cm² group and the short 0.45 ms pulse duration with 6 J/cm² 
group; however, the pain was statistically significantly more intense in the longer pulse 
group (Treewittayapoom et al, in press). 
9.3.3 Ionising radiation 
Superficial radiotherapy delivers the radiation energy mainly to the skin surface. Three 
patients were treated with 400 to 600 cGy. Although no changes were noted during the 4-
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month treatment interval the nails regrew normally in the following 8 to 14 months, and one 
patient had disease-free nails even 20 years after cessation of the irradiation (Finnerty, 1979). 
Another ten patients were treated in a randomized prospective double-blind study with 
twice fractioned doses of 150 cGy superficial radiotherapy each a week apart. One hand was 
treated and the other left for comparison. After 10 and 15 weeks posttreatment, the 
irradiated hand was significantly better concerning pitting, subungual hyperkeratosis, 
onycholysis, total nail destruction and nail thickness, but afte 20 weeks no difference was 
seen anymore between the treated and untreated hands (Yu and King, 1992). 
Grenz rays are very soft X-rays not penetrating the skin. In a randomized, double-blind 
study of 22 patients, 5 Gy of Grenz rays were applied in ten weekly courses to one hand 
only. Only 1 patient showed complete clearance, 7 mild improvement and 14 remained 
unchanged. Only non-hyperkeratotic lesions responded, which might have to be expected as 
Grenz rays do not penetrate the skin and hyperkeratosis. Six months after the irradiation, 2 
patients were improved, two had worsened, and 18 remained unchanged. Slight nail fold 
pigmentation was the only adverse effect (Lindelöf, 1989). 
Electron beam therapy was chosen by another group as the electrons are able to penetrate 
the nail bed (Kwang et al, 1995). Twelve patients were treated on one hand with a weekly 
dose of 750 cGy for a period of 8 weeks. Assessment at 3, 6 and 12 months showed 
improvement in 3 patients, slight improvement in 6 subjects, and a complete failure in 3 
individuals after 3 months. At 6 and 12 months, only one patient continued to improve, 9 
regressed to pretreatment conditions. A temporary deep brown-black discoloration of the 
treated nails was observed in some subjects.  
All ionizing treatments have to be used with utmost care as long-term side effects may 
occur, often so late that the patient does not remember to have been treated with this 
modality. 
9.3.4 Climatotherapy 
Climatotherapy, in particular balneotherapy in sunny regions, is very popular in countries 
with little sunshine. It often has a positive  effect on the skin and the emotional aspect of the 
patients. Although some patients claim that also their nails improve there are no systematic 
evaluations of the treatment modality on psoriatic nails. 
9.4 Systemic therapies 
Systemic treatments are indicated when there is wide-spread skin involvement. Isolated nail 
psoriasis is rarely seen as an indication for systemic therapy. All systemic treatments known 
to reduce skin lesions will also have a beneficial effect on nail lesions. Controlled studies are 
as a whole rather rare.  
9.4.1 Immunosupressive treatments 
Corticosteroids have for a long time given to psoriatics although their disadvantages such 
as general steroid adverse effects, tachyphylaxis and rebound phenomenon have been 
known for decades. There are no controlled trials of systemic steroids in nail psoriasis. 
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Cyclosporine is a powerful immunosuppressive agent used successfully in wide-spread 
psoriasis. Nail lesions usually also respond favorably. In a median dose of 2.5 mg/kg 
bodyweight daily, cyclosporine effectively reduces skin and nail psoriasis. In a comparative 
trial, cyclosporine versus etretinate were given to 210 patients two thirds of whom had nail 
involvement. At the end of 10 weeks, both groups showed slight improvement of their nails 
which continued in the group that continued with tapered cyclosporine (Mahrle et al, 1995). 
Another patient was treated for her severe nail psoriasis with cyclosporine 3mg/kg/d, and 
the dose was increased twice by one mg after 4 weeks each. After 16 weeks, both skin and 
nails had improved with the nail improvement having been considerably faster. “Proximal 
nail clearing” was observed to be 45 to 60%. The patient stopped cyclosporine on her own 
because of drug-induced hypertrichosis (Arnold et al, 1993). In a retrospective evaluation, 
cyclosporine was found to improve the NAPSI score after 12, 24 and 48 weeks by 40%, 72%, 
and 89%, respectively (Sánchez-Regaña et al, 2011).  
Cyclosporine adverse effects, such as gastrointestinal symptoms, fatigue, leg cramps, 
diastolic blood pressure increase, and peripheral oedema were more common than in the 
etretinate group that suffered more skin symptoms like dry skin, cheilitis, and dry mouth 
(Mahrle et al, 1995). 
Even though there are many reports on treatment of moderate to severe skin psoriasis 
with methotrexate, tacrolimus, mycophenolate mofetil, hydroxyurea, 6-thioguanine, 
sulfasalazine, fumaric esters, azathioprine, carbamazepine, calcitriol, and 
propylthiouracil, controlled studies concerning nail lesions in these patient cohorts are 
lacking. However, one may assume that they might also improve nail lesions when they 
are able to improve the skin. 
Methotrexate is still often administered for wide-spread skin psoriasis although lung, 
liver and kidney fibrosis are well documented adverse effects of long-term treatment. 
There is only one report specificially relating to MTX low dose therapy for 20-nail 
psoriasis (Lee, 2009). In an evaluation of patients with nail psoriasis treated systemically, 
MTX produced NAPSI score improvements of 7%, 31%, and 35%, respectively, after 12, 24 
and 48 weeks (Sánchez-Regaña et al, 2011). MTX as a classical cytostatic drug not only 
inhibits the inflammatory and hyperproliferative processes of psoriasis but may also slow 
down nail growth speed making it difficult to observe a positive effect in a reasonable 
time period. 
9.4.2 Retinoids 
Retinoids are vitamin A derivatives that are used for disorders of keratinisation. Their use 
in skin psoriasis is well documented with a number of studies. However, their potentials 
in nail psoriasis have not independently and systematically be studied (Tosti et al, 2009). 
In a comparative evaluation, acitretin was found to reduce the NAPSI score after 12, 24 
and 48 weeks by 19%, 41%, and 52%, respectively during the treatment of moderate to 
severe skin psoriasis (Sánchez-Regaña et al, 2011). Acitretin is a first-line drug in pustular 
psoriasis, reduces subungual hyperkeratosis  and improves symptoms in severe nail 
psoriasis (Duhard-Brohan, 1999, Piraccini et al, 2001, Tosti et al, 2009). Apart from the 
many potential side effects of retinoids, they may be onychodestructive in high doses as is 
high-dose vitamin A (Baran 1986). 
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9.4.3 Nimesulide 
Nimesulide is a non-steroidal anti-inflammatory agent. After first positive experience 
(Piraccini e al 1994) it was given to 13 patients with pustular nail psoriasis of whom 4 
responded well to twice daily 100 mg. All these 4 responders relapsed after withdrawal of 
the drug (Piraccini et al 2001). It was judged as not being superior to other drugs.  
9.4.4 Biologics 
An increasing number of “biologics” have been developed in the last decade. They 
counteract extremely potent immunological targets such as tumor necrosis factor-α (TNF-α), 
T cells, B cells, various cytokines, some immunoglobulins and key enzymes. A variety of 
them has been used in psoriasis, often with astonishing success (Lawry, 2007). Also nail 
psoriasis was the object of some studies. This chapter is, however, not suited to discuss all  
as this will be discussed in the psoriasis treatment chapters. 
9.4.4.1 TNF-inhibitors 
TNF- promotes cytokine secretion, such as interleukin (IL)-1, IL-6, IL-8, by macrophages and 
other inflammatory cells, activates T cells and induces adhesion molecule expression by 
vascular endothelial cells which in turn promote angiogenesis and keratinocyte proliferation, 
both key events in the pathogenesis of psoriasis (Smolen and Emery, 2011).  
 
 Infliximab 
Remicade®  
Adalimumab 
Humira® 
Etanercept  
Enbrel® 
Structure Chimaeric antibody Human monoclonal 
antibody 
Human fusion protein 
Application Intravenous infusion Subcutaneous Subcutaneous 
Dosage 5 mg/kg at weeks 0, 
2, 6, then every 8 
weeks 
Loading dose: week 0 
2x40 mg, week 1 40 
mg, then 40 mg every 
2 weeks 
50 mg/week, or 
2x50mg/week for 12 
weeks 
Indications Psoriasis, psoriatic 
arthritis 
Psoriasis, psoriatic 
arthritis 
Psoriasis, psoriatic 
arthritis 
Table 5. Application, dosage and indications of the commonly used TNF- antagonists 
Infliximab (Remicade®) is an inhibitor of TNF-, which is a proinflammatory cytokine in 
psoriasis, psoriatic arthritis, ankylosing spondylitis, Reiter’s disease and several more 
chronic inflammatory diseases. Given as an intravenous infusion of 5 mg/kg at weeks 0, 
2, 6, and then every 8 weeks, infliximab, a chimeric monoclonal antibody, is effective in 
psoriasis, psoriatic nail lesions (Reich et al, 2005), psoriatic arthritis and Reiter’s disease 
including its nail changes (Gaylis, 2003). Many reports have described the dramatic 
infliximab-induced improvement of both psoriatic skin and nail lesions (Antoni et al, 
2005a, 2005b, Rich et al, 2008, Hussain et al, 2008,  Reich, 2009). Another study showed a 
reduction of the mean NAPSI of 55.8 at baseline to 29.8 at week 14 and 3.3 at 38 
(Rigopoulos et al, 2008). In the evaluation mentioned above, NAPSI improvement after 12, 
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24 and 48 weeks was 50%, 81%, and 92%, respectively (Sánchez-Regaña et al 2011). There 
appears to be general agreement that infliximab is the most potent antipsoriatic biologic 
(Noiles and Vender, 2009). 
Adalimumab (Humira®) is a human antibody. In an open study, significant NAPSI 
reductions were obtained for finger and toe nails both in patients with cutaneous psoriasis 
as well as with psoriatic arthritis (Rigopoulos et al, 2010). In a large cohort of 442 patients 
with psoriatic arthritis, the mean NAPSI was reduced by 44% (Van den Bosch et al, 2010). 
Nail psoriasis response may be rapid (Irla and Yawalkar, 2009) although some authors 
found skin lesions to respond less than articular inflammation (Otten et al, 2011). In a group 
of ankylosing spondylitis and psoriatic arthritis patients, the NAPSI score was demonstrated 
to be reduced by 6 points (Rudwaleit  et al, 2010). Adalimumab-induced improvement in 
nail psoriasis correlated with a good response in palmar plantar psoriasis (Langley et al, 
2011). In the Spanish study, NAPSI improvement after 12, 24 and 48 weeks was  37%, 73%, 
84%, respectively. Adalimumab was also beneficial for nail psoriasis after etanercept 
treatment (Puig et al, 2010). 
Etanercept, a fully human  TNF-α receptor fusion protein, binds TNF-α with greater 
affinity than natural receptors. The bound TNF-α is biologically inactive and many of the 
proinflammatory pathways responsible for initiation, maintenance, and recurrence of skin 
lesions in psoriasis are inhibited (Weinberg, 2003). The starting dose is twice weekly 50 
mg subcutaneously, which may be reduced to once weekly 50 mg or twice weekly 25 mg. 
In a comparison of systemic nail psoriasis treatments, NAPSI improvement after 12, 24 
and 48 weeks was 24%, 68%, and 87%, respectively (Sánchez-Regaña et al, 2011). The 
commonest adverse effect is an irritation reaction at the injection site. Infections and 
reactivations may occur as in infliximab treatment though probably less commonly. It 
should not be combined with systemic corticosteroids (Sanchez et al, 2006, Scheinfeld, 
2004). There are some otherwise rare skin diseases that have been observed during 
etanercept treatment, such as lupus erythematosus, vasculitis, eosinophilic cellulitis like 
inflammation and interstitial granulomatous dermatitis (Scheinfeld, 2004, Winfield et al, 
2006, Deng et al, 2006).  
Golimumab (Simponi®) is a new human monoclonal antibody against TNF- binding with 
high affinity and specificity to soluble and transmembrane TNF-. It was studied once in 
psoriasis and nail psoriasis and showed an improvement in the NAPSI score of 25% and 
43% after 14 weeks and 33% and 54% after 24 weeks in a dose of 50mg or 100 mg 
subcutaneously, respectively, at weeks 0, 4, 8, 12, 16, and 20 (Kavanaugh et al, 2009). 
Certulizumab (Cimzia®) has not been used in nail psoriasis (Gartlehner et al, 2009). 
All TNF- inhibitors were reported to have induced psoriasis or psoriasiform skin and nail 
lesions (Sfikakis et al, 2005, Wollina et al, 2010). The spectrum of conditions induced by 
TNF- is very wide and it apparently does not depend on the specific disease treated nor on 
the anti-TNF- agent used (Pine et al, 2010, Conrad et al, 2011; Lee et al 2011). In more than 
half of the cases, the TNF- induced skin lesions were successfully suppressed despite 
continuation of the drug. It is speculated that as TNF- blockade is one of the strongest 
inducers of interferon- production an unabated IFN- production by plasmocytoid 
dendritic cells might result in these paradoxical psoriasis flares under anti-TNF- treatment 
(Conrad et al, 2011).  
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Serious adverse events of all TNF- inhibitors include the development of viral, bacterial, 
mycobacterial, and fungal infections (Lowther et al, 2007), reactivation of tuberculosis, 
hepatitis B and C, allergic infusion reactions, malignancies, autoantibody formation with 
lupus erythematosus, pancytopenia and aplastic anaemia, neurological disorders and 
worsening of congestive heart failure (Smolen and Emery, 2011). Experience in pregnancy 
is lacking. Further, infliximab comes with an information what to look for before starting 
a treatment. Paradoxical sarcoidosis while on anti-TNF- treatment was also reported 
(Pine et al, 2010) 
9.4.4.2 T cell inhibitors 
Alefacept (Amevive®) is a human recombinant fusion protein composed of LFA-3 with the 
Fc portion of human IgG. In psoriasis, the inflammatory response is amplified when LFA-3 
molecule-containing antigen presenting cells bind to the CD2+ receptor of T cells, the result 
being T cell activation and the release of proinflammatory cytokines. Alefacept binds to the 
CD2+ receptor of T cells via its LFA-3, thus blocking this interaction with antigen-presenting 
cells. Furthermore, alefacept triggers apoptosis of memory T cells. Through these two 
mechanisms, alefacept decreases the number of pathogenic T cells in psoriasis (Weinberg, 
2003, Lawry 2007). 
Alefacet is usually given in a dose of 15 mg per week for a period of 12 weeks; intravenous 
administration is also possible. At baseline, the CD4+ T cells should be monitored and then 
every 2 weeks. A CD4+ count below 250/µl should prompt to withhold the treatment until 
it has recovered. As alefacept has proven to be very safe the 2-weekly CD4 cell count may be 
delayed. Side effects include pruritus, headache, fatigue, nausea, viral upper respiratory 
infections, and arthralgias. Malignancy and serious infections do not appear to occur more 
frequently with alefacept use (Scheinfeld, 2005). 
There are few studies and reports on alefacept use in nail psoriasis (Körver et al, 2006, 
Parrish et al, 2006). In moderate nail psoriasis, 2 patients improved, 2 remained unchanged 
and one worsened (Körver et al, 2006). 
Efalizumab (Raptiva®) is a humanized  monoclonal antibody against the CD11 portion of 
the LFA-1 molecule on lymphocytes. LFA-1 usually binds to intercellular adhesion molecule 
and promotes lymphocyte migration. The binding of efalizumab to CD11a cells is reversible 
and does not deplete T cells, but it prevents them from migrating into the skin (Weinberg, 
2003). It has shown efficacy in the treatment of cutaneous and nail psoriasis but the 
European Medicines Agency (EMA) recommended its suspension of the marketing 
authorization after the occurrence of cases of progressive multifocal leukoencephalopathy 
(19 February 2009 Doc. Ref. EMEA/CHMP/20857/2009). 
Cytokine inhibitors 
Ustekinumab (Stelara®) is a new human IgG1k monoclonal antibody to the p40 epitope 
common to both IL-12 and IL-23. It blocks the differentiation and expansion of T helper cells 
1 and 17 (Leonardi et al, 2008). It is indicated in moderate-to-severe psoriasis resistant to 
other therapies or with contraindications or intolerance to other systemic treatments. 
Ustekinumab is given in a dose of 45 mg for individuals under 100 kg body weight. In a 
patient who had earlier etanercept and failed to respond later ustekinumab was given and a 
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marked improvement of his nail signs was noted after 4 weeks. A complete cure was 
achieved 4 weeks later after the second injection (Rallis et al, 2010). 
Tocilizumab (Actemra®) is an IL-6 receptor inhibitor. No reports on nail psoriasis treatment 
have been published hitherto. 
T cell inhibitors 
Abatacept (Orencia®) is a soluble chimeric protein consisting of the extracellular domain of 
human CD152 linked to the modified Fc portion of human IgG1. By binding to B7-1 (CD80) 
and B7-2 (CD86) molecules on antigen presenting cells, CTLA4Ig blocks the CD28-mediated 
costimulatory signal for T cell activation. Success with abatacept has been noted in psoriasis. 
Abatacept was administered to two patients with refractory psoriasis and psoriatic arthritis 
after the patients had failed all conventional treatment methods. Both patients experienced 
very brief improvement in disease (Altmeyer et al, 2011). 
Rituximab, a B cell depleting chimeric antibody has no place in the treatment of nail 
psoriasis. 
9.5 Combined treatments 
In clinical routine, different treatments are often combined as one is either insufficient or too 
slow. The combination should always consist of drugs with different mechanisms of action. 
In contrast to skin psoriasis, there are almost no studies on the effect of combination therapy 
on nail psoriasis (Jiaravuthisan et al 2007). A single-blinded study on 54 patients with nail 
psoriasis examined the effects of cyclosporine monotherapy versus cyclosporine 
systemically plus calcipotiriol cream topically (Feliciani et al 2004). The cyclosporine dose 
was 3.5 to 4.5 mg/d, calcipotriol was applied twice daily. After 3 months, the combined 
treatment showed significant improvement of pitting, subungual hyperkeratosis and 
onycholysis in 79%, whereas the cyclosporine monotherapy group showed 48% marked 
improvement. Six months after treatment, the cyclosporine monotherapy group showed a 
relapse rate of 52.9% (9/17), whereas only 37% (10/27) of patients in the combined therapy 
group had any signs of recurrence. 
10. Conclusion 
Nail psoriasis is frequent in psoriatic subjects with about 50% of psoriasis patients 
presenting with nail changes at any time and a life-time prevalence of up to 90%. Nail 
psoriasis has a strong genetic background and a frequent association with psoriatic 
arthritis. The most frequent signs of nail matrix involvement are pitting, leukonychia, 
crumbling and red spots in the lunula, whereas salmon or oil spots, subungual 
hyperkeratosis, onycholysis and splinter haemorrages represent changes of nail bed 
involvement. Understanding the mechanism of psoriatic nail sign development requires 
some basic knowledge of the nail organ, its specific reaction patterns and of nail 
histopathology. Nail psoriasis has a serious impact on the quality of life interfering 
particularly with manual work but also being cosmetically embarrassing. Treatment of 
nail psoriasis is difficult as the matrix pathology is hidden by the proximal nail fold and 
the nail bed changes are protected against treatment by the overlying nail plate and nail 
bed hyperkeratosis. Progress has been made with the new biologic drugs, which are 
however, usually only administered for skin plus nail involvement.  
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